CN111683658A - 用于创伤性脑损伤及其后遗症的多蛋白复合物抑制剂疗法 - Google Patents

用于创伤性脑损伤及其后遗症的多蛋白复合物抑制剂疗法 Download PDF

Info

Publication number
CN111683658A
CN111683658A CN201880052529.4A CN201880052529A CN111683658A CN 111683658 A CN111683658 A CN 111683658A CN 201880052529 A CN201880052529 A CN 201880052529A CN 111683658 A CN111683658 A CN 111683658A
Authority
CN
China
Prior art keywords
bbb
multiprotein complex
permeable
complex inhibitor
tbi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880052529.4A
Other languages
English (en)
Chinese (zh)
Inventor
B.P.沃尔纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samus Treatment Co ltd
Original Assignee
Samus Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samus Treatment Co ltd filed Critical Samus Treatment Co ltd
Publication of CN111683658A publication Critical patent/CN111683658A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F17/00—First-aid kits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880052529.4A 2017-06-23 2018-06-22 用于创伤性脑损伤及其后遗症的多蛋白复合物抑制剂疗法 Pending CN111683658A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762524452P 2017-06-23 2017-06-23
US62/524,452 2017-06-23
US201762532989P 2017-07-14 2017-07-14
US62/532,989 2017-07-14
PCT/US2018/038893 WO2018237211A2 (en) 2017-06-23 2018-06-22 Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof

Publications (1)

Publication Number Publication Date
CN111683658A true CN111683658A (zh) 2020-09-18

Family

ID=64737388

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880052529.4A Pending CN111683658A (zh) 2017-06-23 2018-06-22 用于创伤性脑损伤及其后遗症的多蛋白复合物抑制剂疗法

Country Status (10)

Country Link
US (1) US20210161902A1 (enExample)
EP (1) EP3641751A4 (enExample)
JP (1) JP2020525451A (enExample)
KR (1) KR20200019220A (enExample)
CN (1) CN111683658A (enExample)
AU (1) AU2018290288A1 (enExample)
CA (1) CA3068274A1 (enExample)
IL (1) IL271387A (enExample)
TW (1) TW201919613A (enExample)
WO (1) WO2018237211A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913562VA (en) * 2017-04-24 2020-03-30 Samus Therapeutics Inc Hsp90 inhibitor oral formulations and related methods
WO2023097071A2 (en) * 2021-11-29 2023-06-01 The Regents Of The University Of California Methods for treating traumatic brain injury

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005937A2 (en) * 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
US20110201587A1 (en) * 2010-02-16 2011-08-18 Bio Holding, Inc. Hsp90 inhibitors and methods of use
US20160264577A1 (en) * 2011-04-05 2016-09-15 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
CN110996918A (zh) * 2017-04-24 2020-04-10 萨缪斯治疗股份有限公司 Hsp90抑制剂口服配制品和相关方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599138A (en) * 2009-10-07 2014-06-27 Sloan Kettering Inst Cancer Purine derivatives useful as hsp90 inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005937A2 (en) * 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
US20110201587A1 (en) * 2010-02-16 2011-08-18 Bio Holding, Inc. Hsp90 inhibitors and methods of use
US20160264577A1 (en) * 2011-04-05 2016-09-15 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
CN110996918A (zh) * 2017-04-24 2020-04-10 萨缪斯治疗股份有限公司 Hsp90抑制剂口服配制品和相关方法

Also Published As

Publication number Publication date
EP3641751A2 (en) 2020-04-29
WO2018237211A3 (en) 2019-03-14
EP3641751A4 (en) 2021-03-31
KR20200019220A (ko) 2020-02-21
US20210161902A1 (en) 2021-06-03
AU2018290288A1 (en) 2020-01-16
JP2020525451A (ja) 2020-08-27
IL271387A (en) 2020-01-30
WO2018237211A2 (en) 2018-12-27
CA3068274A1 (en) 2018-12-27
TW201919613A (zh) 2019-06-01

Similar Documents

Publication Publication Date Title
TWI887465B (zh) 用於伊卡洛斯(ikaros)或愛露斯(aiolos)介導之病症之有利療法
JP6434416B2 (ja) ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
US20110262442A1 (en) Compositions for treating cns disorders
ES2678250T3 (es) Tratamiento del cáncer con inhibidores de quinasa TOR
TW201625259A (zh) 醫藥用途
JP2023029899A (ja) 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法
JP5208113B2 (ja) 特定のエンドセリン受容体アンタゴニストとｐｄｅ５阻害剤を含む治療用組成物
CN112472699A (zh) 改善比生群及衍生物的治疗益处的组合方法
EP2175724A1 (en) Methods and compositions for treating schizophrenia using antipsychotic combination therapy
KR20160061911A (ko) 최적하 투여된 화학 화합물의 치료 효과
TW200538128A (en) Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
WO2000069464A1 (en) Novel use
US20060211686A1 (en) Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions
CN111683658A (zh) 用于创伤性脑损伤及其后遗症的多蛋白复合物抑制剂疗法
JP7007559B2 (ja) 白内障の予防剤および治療剤、並びに、これらを製造するための、ｄｎａ損傷に応答するシグナル伝達経路を阻害する阻害剤の使用
JP2018520102A (ja) エベロリムスとダクトリシブとの薬学的組合せ
KR20170117185A (ko) 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘
US7888341B2 (en) Combination of glivec (STI571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer
CN117999073A (zh) 纳多洛尔通过阻断抑制蛋白-2途径来治疗慢性阻塞性肺病的用途
CA2416706C (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
JP2021505559A (ja) 組合せ製品を用いるｒｓｖの処置
TW201904570A (zh) 治療肝癌之方法
EP4083044A1 (en) Use of triazolotriazine derivative in treatment of diseases
WO2018106118A1 (en) Treatment of diffuse intrinsic pontine glioma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200918

WD01 Invention patent application deemed withdrawn after publication